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Abstract: Aggressive carcinomas ferment glucose to lactate even in the presence of oxygen. This particular metabolism, 
termed aerobic glycolysis, the glycolytic phenotype, or the Warburg effect, was discovered by Nobel laureate Otto Warburg 
in the 1920s. Since these times, controversial discussions about the relevance of the fermentation of glucose by tumours 
took place; however, a majority of cancer researchers considered the Warburg effect as a non-causative epiphenomenon. 
Recent research demonstrated, that several common oncogenic events favour the expression of the glycolytic phenotype. 
Moreover, a suppression of the phenotypic features by either substrate limitation, pharmacological intervention, or genetic 
manipulation was found to mediate potent tumour-suppressive effects. The discovery of the transketolase-like 1 (TKTL1) 
enzyme in aggressive cancers may deliver a missing link in the interpretation of the Warburg effect. TKTL1-activity could 
be the basis for a rapid fermentation of glucose in aggressive carcinoma cells via the pentose phosphate pathway, which 
leads to matrix acidiﬁ  cation, invasive growth, and ultimately metastasis. TKTL1 expression in certain non-cancerous tissues 
correlates with aerobic formation of lactate and rapid fermentation of glucose, which may be required for the prevention of 
advanced glycation end products and the suppression of reactive oxygen species. There is evidence, that the activity of this 
enzyme and the Warburg effect can be both protective or destructive for the organism. These results place glucose metabo-
lism to the centre of pathogenesis of several civilisation related diseases and raise concerns about the high glycaemic index 
of various food components commonly consumed in western diets.
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diagnostics, as well as recombinant cell culture systems for 
complex functional analyses of cancer-relevant genes. In 
2006, Rainer Wittig joined R-Biopharm to coordinate basic 
research in cooperative projects with universitary partners, 
and to establish diagnostic tools for the biomarkers TKTL1 
and DNaseX.
Introduction
Constitutive activation of signalling pathways by 
oncogenic events or loss of (tumour) suppressive 
functions is considered to be causative for tumour-
igenic conversion as well as tumour progression. 
Progress at the technological level allowed research-
ers to delineate cancer relevant signalling as well 
as to discover both connections and dependencies 
between dominant growth/survival pathways and 
their negatively regulating counterparts. As foreseen 
by Hanahan and Weinberg in their frequently cited 
review article “the hallmarks of cancer” (2000), 
research tends to move away from single-event 
analysis towards more complex analyses, culminat-
ing in the advent of systems biology (Kirschner, 
2005). This yet poorly deﬁ  ned biological discipline 
is still in its infancies, but the trend already revealed 
that in most cases understanding cancer cannot 
result from the view on a single oncogenic event, 
but must consider the combined action of both 
extracellular and intracellular triggers in a given 
cellular background. As a further layer of complex-
ity, cancer cells are genetically instable, which 
means that they actively respond to both types of 
signals by somatic evolution and in most cases 
ultimately develop an aggressive phenotype. The 
latter is characterized by certain almost invariant 
properties, which include those described by 
Hanahan and Weinberg (self-sufﬁ  ciency in growth 
signals, insensitivity to antigrowth signals, evasion 
from apoptosis, limitless replicative potential, sus-
tained angiogenesis, and tissue invasion and metas-
tasis; Hanahan and Weinberg, 2000) as well as an 
energetically ineffective metabolism which mainly 
relies on the fermentation of glucose (Garber, 2004). 
Thus, in a more philosophical way, cancer cells may 
be seen as autonomous parasites within the body, 
which have lost the ability to fulﬁ  l their job in a 
given tissue, but instead develop strategies to gain 
independence (Pfeiffer et al. 2001).
In 1861, Louis Pasteur recognized that aerobic 
respiration (oxidative phosphorylation, OXPHOS) 
in yeast is suppressed by anaerobiosis, resulting in 
fermentative metabolism and the utilization of 
elevated amounts of glucose. Vice versa, the 
presence of oxygen suppresses glycolysis (the 
Pasteur effect). Roughly 60 years later, Nobel laure-
ate Otto Warburg described the surprising phenom-
enon of elevated “aerobic glycolysis”, i.e. a 
fermentative glucose metabolism in the presence of 
oxygen, in cancerous tissues as well as in certain 
healthy tissues (Warburg et al. 1924). Decades later 
glycolysis via the Embden-Meyerhof pathway 
(Fig. 1) has been identiﬁ  ed, and this way of glucose 
degradation has also been named glycolysis. How-
ever, as discussed in this review, the underlying 
molecular and biochemical bases of these two types 
of glycolysis are probably not identical. Therefore, 
the use of a single term for two different ways of 
glucose cleavage may have led to fatal misinterpre-
tations of metabolic changes in tumours. In his 
original work, Warburg analysed the ratio of 
OXPHOS to glycolysis in different tissues and 
cancer cells and documented a particular metabo-
lism in cancer and certain other tissues. Glycolysis 
under aerobic conditions was particularly high in 
aggressive cancers when compared to benign car-
cinomas and normal tissues. Elevated values for 
aerobic glycolysis were also found in testicular and 
retinal tissue. Warburg found a suppression of res-
piration in embryonic tissue and elevated glycolysis 
following exposure to cyanide and molecular 
nitrogen. Nitrogen evoked irreversible suppression 
of respiration. Based on his ﬁ  ndings, Warburg pro-
posed respiration deﬁ  ciency and an increase of 
glucose fermentation as a primary cause for cancer 
(Warburg et al. 1924; Warburg, 1956). This inter-
pretation was shared by another Nobel laureate, 
Albert Szent-Györgyi, who postulated that cancer 
results from a higher degree of cellular disorder, a 
relapse to the obligate proliferative (anaerobic) alpha 
state of life (Szent-Györgyi, 1980). Therefore both 
Nobel laureates postulated that cancer is the result 
of a switch from an oxygen based energy production 
to an anaerobic, fermentative energy production.
For decades, Warburgs hypothesis was subject 
of severe discussion. Subsequent to advances in 
molecular biology and genetics, research primarily 
focused on the characterization of common genetic 
aberrations in cancer, whereas aerobic glycolysis 
was frequently considered to be a non causative 
epiphenomenon. However, several of these genetic 
insults and the resulting alterations in cellular sig-
nalling have been found to be intimately linked to 
progressive loss of respiration as well as elevated 
glycolysis in carcinoma cells. Strikingly, glucose 
fermentation is linked to aggressiveness in cancers 66
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Figure 1. Schematic illustration of different pathways of glucose metabolism in cancer cells. Glucose enters the cell via glucose transporter 
proteins (GLUT). Metabolic ﬂ  ux rates in different pathways are determined by the regulation of rate-limiting enzymes as described in the 
text, as well as by the balanced equilibrium of respective intermediates. Enzymes, reactions, and intermediates of the Embden-Meyerhof 
pathway are coloured in red, whereas those of the PPP are coloured in blue. Selected enzymes which are referred to in the text are listed 
at their respective positions. The oxidative branch of the PPP delivers ribose-5-phosphate for the biosynthesis of nucleotides, as well as 
NADPH for reductive biosynthesis, for the regulation of the redox state within the cell, and for the detoxiﬁ  cation of ROS. Within the illustra-
tion of the non-oxidative PPP, C3, C7, C6, and C4 indicate sugar phosphate intermediates, which are interconverted in equilibrium reactions 
by the transketolase and transaldolase enzymes. Xylulose-5-phosphate, the concentration of which determines the ﬂ  ux rates through both 
major pathways, may be generated from glucose-6-phosphate via the oxidative or the non-oxidative branch of the PPP. It may serve as a 
substrate for TKTL1 in a putative cleavage reaction, which generates GAP and a 2-carbon unit, probably acetyl-CoA. Cytosolic acetyl-CoA 
is utilized for glucose-induced lipogenesis. GAP, which is also generated in the Embden-Meyerhof pathway, may be further metabolized 
either in the Embden-Meyerhof pathway, or via methylglyoxal to D-lactate. In cancer cells, the generation of L-lactate from pyruvate is pre-
dominantly catalyzed by LDHA. Both lactate stereo-isomers are in an equilibrium with pyruvate. Since the oxidation of pyruvate is frequently 
inhibited in cancer cells (see text), high amounts of lactate are exported via monocarboxylate transporters (MCT).
independent of the origin and is diagnostically 
exploited by the utilization of [
18F] fluoro-2-
deoxyglucose positron emission tomography 
(FDG-PET) (Kelloff et al. 2005). Also, inhibitors 
of carbohydrate metabolism were found to exhibit 
profound anti-tumourigenic effects (Rais et al. 1999; 
Du et al. 2004; Zhang et al. 2006; Ramos-Montoya 
et al. 2006). Therefore, during recent years tumour 
bioenergetics returned back into the focus of cancer 
research, and now prominent researchers consider 
aerobic glycolysis as an additional hallmark of can-
cer (reviewed in Garber, 2006).
Oncogenic Signalling and the 
Glycolytic Phenotype of Cancer Cells
The metabolism of aggressive cancer cells is fre-
quently dominated by a consumption of large 
amounts of glucose, which exceeds the needs of 
normal cells about 20–30 fold. Metabolic proﬁ  ling 
experiments utilizing labelled substrate revealed, 
that carbon atoms of glucose predominantly appear 
in lactate, fatty acids, and in nucleic acid-associated 
ribose (Boros et al. 2002). This distribution 
reﬂ  ects both the high proliferation rate as well 
as the reduction of OXPHOS in aggressive 
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cancer cells. Glucose may be fermented by the 
Embden-Meyerhof glycolytic pathway (Fig. 1), 
which includes different rate-limiting and well 
regulated reactions. As described in this section, 
oncogenic signalling was found to interfere with 
the regulation of this pathway. The pentose phos-
phate pathway (PPP) represents an alternative route 
for anaerobic glucose degradation (Fig. 1), which 
will be discussed in more detail in the chapters 
below. Since it is not yet clear, how glucose is 
fermented in aggressive cancer cells (Coy et al. 
2005), within this paper the term “glycolysis” may 
be solely seen as the degradation of glucose, irre-
spective of the enzymes involved.
In an elegant experiment, Ramanathan et al. 
(2005) analyzed metabolic alterations within a 
cellular system for cancer initiation and progres-
sion, which was modelled by the serial integration 
of oncogenes. Metabolic proﬁ  ling revealed a pro-
gressive loss of respiration and an accompanying 
dependence on glycolysis for cell growth. The ﬁ  nal 
introduction of the ras oncogene, which reﬂ  ects a 
genetic aberration commonly observed in a variety 
of tumours, ultimately boosted resistance to oligo-
mycin, an inhibitor of OXPHOS in these cells. The 
enhanced dependency on glycolysis was docu-
mented by an elevated sensitivity to 2-deoxyglucose, 
a potent inhibitor of glycolysis. The authors con-
cluded that the two models of carcinogenesis, 
i.e. the Warburg hypothesis and the model based 
on cancer causing genes, are interlinked rather than 
being opposing models (Ramanathan et al. 2005). 
As described below, additional complex interac-
tions between major oncogenic pathways deter-
mine the metabolic fate of a cancer cell, and most 
of the mechanisms, which lead to the phenotypic 
expression of the commonly accepted hallmarks 
of cancer (Hanahan and Weinberg, 2000) also 
favour the realization of the glycolytic phenotype 
in cancer cells.
The contribution of oncogenic ras to the glyco-
lytic phenotype was recognized more than 20 years 
ago (Racker et al. 1985). More recently, detailed 
mechanisms leading to elevated glycolysis through 
ras signalling in cancer cells have been elucidated. 
Mazurek et al. (2001) found elevated levels of the 
glycolytic intermediate fructose 1,6-bisphosphate 
(FBP) in ras-transformed cells, which was accom-
panied by tetramerization and enhanced activity 
of the pyruvate kinase M2 isoenzyme. In another 
study, pharmacologic inhibition of ras signalling 
was found to provoke shutdown of glycolysis and 
subsequent cell death in glioblastoma cells (Blum 
et al. 2005).
Another well known key player in oncogenesis, 
the c-myc transcription factor, was demonstrated 
to transactivate the lactate dehydrogenase A 
(LDHA) gene, leading to an elevated production 
of lactic acid from pyruvate (Shim et al. 1997). The 
relevance of LDHA function for tumourigenicity 
was recently demonstrated in an RNAi-approach. 
Repression of LDHA stimulated OXPHOS and 
compromised the ability to proliferate during 
hypoxia (Fantin et al. 2006). C-myc-transformed 
cells were found to undergo apoptosis upon glucose 
deprivation (Shim et al. 1998). Besides LDHA, 
c-myc was found to transactivate a variety of other 
genes necessary for the glycolytic phenotype 
(Osthus et al. 2000). Recently, c-myc was demon-
strated to initiate transcription of vascular endothe-
lial growth factor (VEGF, an inducer of 
angiogenesis) in response to hypoxia and PI3K 
signalling (Mizukami et al. 2006).
Intermittent hypoxia is experienced by almost 
every carcinoma cell and contributes to the stabi-
lization of the heterodimeric transcription factor 
hypoxia-inducible factor 1 (HIF-1), which repre-
sents a key regulatory factor for the phenotypic 
expression of tumour cell proliferation, elevated 
fermentation of glucose, suppression of apoptosis, 
and angiogenesis (reviewed in Semenza, 2003, see 
Fig. 2). Whereas HIF-1β/ARNT is constitutively 
expressed, the HIF-1α subunit is subject to tight 
regulation at the translational level as well as by 
its stability, which is determined by the oxygen 
tension in the cell. HIF-1 is seen as a messenger 
for hypoxia which triggers transcriptional responses, 
the details of which are determined by the respec-
tive cellular background. However, during recent 
years it became increasingly clear that HIF-1 activ-
ity is not merely a response to low oxygen tension. 
HIF-1 was found to be evoked in response to a 
variety of stimuli different to hypoxia, including 
oncogenic signalling by ras (see above), v-src 
(Jiang et al. 1997), MEK-ERK (Fukuda et al. 
2002), EGFR (Zhong et al. 2000), and the PI3K-
AKT pathway (Zhong et al. 2000; Zundel et al. 
2000; Jiang et al. 2001); but also radiation (Moeller 
et al. 2004), reactive oxygen species (ROS) 
(Brunelle et al. 2005; Guzy et al. 2005; Mansﬁ  eld 
et al. 2005) or simply the presence of pyruvate (Lu 
et al. 2002) or the tricarboxylic acid cycle (TCA) 
intermediates fumarate (Isaacs et al. 2005) and 
succinate (Selak et al. 2005). In summary, activators 68
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of HIF-1 reﬂ  ect a loss of metabolic activity in 
mitochondria, which can be caused either by 
defects in the respiratory chain (as suggested by 
Warburg, 1956), or by regulatory insults. Therefore 
it was not surprising, that HIF-1 was found to 
transactivate pyruvate dehydrogenase kinase 1 
(PDK1) (Kim et al. 2006; Papandreou et al. 2006), 
which phosphorylates and inactivates the mito-
chondrial pyruvate dehydrogenase complex (PDC). 
In a feedback loop, this leads to a shutdown of the 
formation of mitochondrial acetyl-CoA and 
OXPHOS, which in turn substantially reduces the 
generation of mitochondrial ROS and contributes 
to the generation of lactate.
Besides the supportive action of HIF-1, several 
studies demonstrated the signiﬁ  cance of PI3K 
signalling for the Warburg effect (Fig. 3). Beneath 
an internal activation by e.g. ras (as described 
above), the PI3K pathway is activated by survival 
signals transmitted from outside the cell via trans-
membrane receptors and mediates cell growth and 
survival, inhibits apoptosis, evokes angiogenesis, 
and activates the glycolytic phenotype (Vivanco 
and Sawyers, 2002; Thompson and Thompson, 
2004, see Fig. 3). PI3K signalling is negatively 
regulated by the phosphatase and tensin homolog 
deleted on chromosome 10 (PTEN), a tumour 
suppressor which is frequently inactivated in a 
variety of cancers (Cully et al. 2006). PI3K signal-
ling results in the activation of AKT and subse-
quently mTOR (reviewed in Thompson and 
Thompson, 2004; Hay, 2005). Intriguingly, PI3K 
Figure 2. The HIF-1 network. The heterodimeric transcription factor HIF-1 consists of a β-subunit (HIF-1β), which is constitutively 
expressed, as well as an α-subunit (HIF-1α), the expression and stability of which is tightly regulated. Destabilizing factors for HIF-1α 
are indicated in red colour, whereas stabilizing factors are indicated in blue colour. Translation of HIF-1α is enhanced by the activity 
of mTORC1 and its downstream activities, which provides a link of HIF-1 activity to survival pathways. The proteolytic degradation 
of HIF-1α is mediated by the proteasome subsequent to ubiquitylation mediated by the von Hippel-Lindau (VHL)-protein. The recog-
nition of HIF-1α is dependent on the hydroxylation of prolyl residues, which is catalyzed by HIF-1 prolyl hydroxylases 1–3 (HPH). 
The activity of HPH is a function of the oxygen tension within the cell. HIF-1α is stabilized by hypoxia as well as by several other 
factors which reflect a loss of metabolic activity in the mitochondria. HIF-1 transactivates a variety of genes which contribute to the 
hallmarks of aggressive cancer. Notably, at least one of the HIF-1 target genes, PDK1, directly represses the TCA and OXPHOS by 
the inhibition of PDC.
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signalling can be directly activated by the loss of 
mitochondrial respiration via a NADH-mediated 
inactivation of PTEN, thereby leading to elevated 
resistance against anticancer drugs and to a sur-
vival advantage in hypoxia (Pelicano et al. 2006b; 
Xu et al. 2005). This ﬁ  nding may explain some 
surprising results from mutational analyses of 
PTEN in different cancers, which revealed fre-
quent hyperactivation of AKT signalling in the 
absence of identiﬁ  able PTEN mutations (reviewed 
in Cully et al. 2006). Also, this mechanism repre-
sents a feed-forward loop, by which loss of 
respiration may trigger a complete switch to 
glycolysis.
The interference of mTOR with the PI3K 
pathway is rather complex and probably not yet 
fully elucidated (reviewed in Sabatini, 2006, see 
Fig. 3). Two cancer relevant complexes (mTORC1 
and mTORC2) have been described, which elicit 
distinct effects within the cell. mTORC1 is activated 
by PI3K signalling via AKT-mediated inhibition of 
its inhibitor, the tuberous sclerosis complex (TSC). 
mTORC1 regulates cell growth via the activation 
of translation and ribosome biogenesis. The 
complex also contributes to elevated translation of 
HIF-1α, which leads to stabilization of HIF-1 and 
the subsequent activation of several genes required 
for elevated glycolysis (see above).
Figure 3. Signalling events which determine glucose utilization within the cell. The PI3K-AKT-mTOR-pathway promotes the glycolytic phe-
notype at various sites via the direct modulation of target proteins as well as on the transcriptional and translational level (for review see 
Thompson and Thompson, 2004; Sabatini, 2006). One key event supporting aerobic glycolysis is the elevated translation of HIF-1α, the 
effects of which are illustrated in Figure 2 and discussed in the text. Mitochondrial ROS activate the PI3K-AKT-mTOR-pathway via redox-
mediated inhibition of PTEN. Active AMPK and rapamycin negatively regulate PI3K-signalling via suppression of mTORC1. Active AMPK 
also regulates a glucose-dependent cell cycle checkpoint via phosphorylation of p53. Intact p53 can further directly regulate both glycolysis 
and OXPHOS via transactivation of its target genes TIGAR and SCO2. Intracellular proteins conferring a suppressive effect on PI3K signalling 
are indicated in dark blue colour, whereas those which promote this pathway and enable the glycolytic phenotype are indicated in light blue 
colour.
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The effects of mTORC1 are sensitive to 
rapamycin, analogues of which are currently under 
investigation for the use as anticancer agents. The 
mTORC2 complex, which is responsive to growth 
factor signalling, directly activates AKT, which leads 
to the confusing situation that mTOR as a protein is 
placed both upstream and downstream of AKT 
activity (Sabatini, 2006; Shaw, 2006). As mTORC1 
activity leads to AKT inhibition via a feedback loop 
initiated through blockade of insulin receptor sub-
strate 1 (IRS1), therapeutic application of rapamycin 
and its analogues may favour the oncogenic func-
tions of activated AKT. Therefore, it is discussed to 
evaluate a combination of both AKT and mTORC1 
inhibitors for anticancer therapy.
Thompson and colleagues demonstrated a 
dependence of glioblastoma cells to glycolysis 
following integration of constitutively activated 
AKT (Elstrom et al. 2004). Subsequently, pharma-
cologic activation of AMP activated protein kinase 
(AMPK), an important sensor of cellular energy 
tension, was found to reverse this dependency 
through the activation of fatty acid beta-oxidation 
(Buzzai et al. 2005). AMPK was recently found to 
be activated through phosphorylation by LKB1 
(Shaw et al. 2004), which is the tumour suppressor 
in the rare autosomal dominant Peutz-Jeghers 
syndrome (PJS). This disease is characterised by 
the onset of gastrointestinal polyps as well as a 
predisposition to tumours in various other tissues 
(Hearle et al. 2006). Compromised AMPK activity 
may explain the tumourigenic phenotype resulting 
from LKB1 mutations, because AMPK itself exerts 
different tumour-suppressive functions. Via phos-
phorylation of the TSC1/2 complex, AMPK inac-
tivates mTORC1 and thereby antagonizes AKT 
signalling (Inoki et al. 2003; Sabatini, 2006). 
Recently, AMPK was found to regulate a glucose 
dependent cell cycle arrest which is mediated by 
phosphorylation of the tumour suppressor p53 
(Jones et al. 2005). However, p53 is inactivated in 
a high percentage of human cancers, and therefore 
this AMPK-controlled metabolic checkpoint is 
frequently disturbed. Interestingly, p53 was also 
found to modulate the balance between utilization 
of respiratory and glycolytic pathways by transac-
tivating SCO2, which plays a key role in OXPHOS 
(Matoba et al. 2006). Another recently identiﬁ  ed 
target for p53-mediated transactivation, TIGAR, 
was found to inhibit glycolysis by inhibiting 
phospho-fructokinase activity (Bensaad et al. 
2006). Therefore, loss of both AMPK as well as 
p53 function in cancer obviously contributes to the 
glycolytic phenotype (see Fig. 3).
In summary, both HIF-1 as well as AKT signal-
ling can be activated by loss of respiration and 
contribute to elevated fermentation of glucose. 
AMPK signalling may confer suppressive effects 
on the glycolytic phenotype and cancer progression 
by forcing mitochondrial activity, but this requires 
the presence and function of other tumour suppres-
sive mechanisms mediated by p53, PTEN, TSC1/
TSC2, and LKB1 which are frequently inactivated 
in cancer (Jones et al. 2005; Liu et al. 2006). How-
ever, AMPK activity was also found to be involved 
in growth and survival of tumour models during 
hypoxic stress and glucose deprivation, independ-
ently of HIF-1 (Laderoute et al. 2006; Liu et al. 
2006). It has been proposed, that AMPK activity 
may be detrimental and therefore suppressed in 
early cancers, while advanced cancers with inac-
tivation of tumour suppressors may reactivate 
AMPK in order to acquire energy via glycolysis 
(Ashraﬁ  an, 2006).
In conclusion, most of the pathway deregula-
tions described above result from cancer speciﬁ  c 
mutations and malfunctions and favour the expres-
sion of the Warburg phenotype. Many researchers 
suggest an enhanced rate of glucose fermentation 
via the Embden-Meyerhof pathway, but still there 
are some phenomena which are difﬁ  cult to explain. 
In many cancers, the formation of pyruvate and 
acetyl-CoA are compromised by the inhibition of 
the respective enzymes, M2-pyruvate kinase (by 
formation of the low afﬁ  nity dimeric form [Zwer-
schke et al. 1999]), and PDC (via PDK1-mediated 
inhibition). Concomitantly, fatty acid synthase 
(FASN), which catalyzes the massively observed 
lipogenesis in cancer cells, was suggested to rep-
resent a metabolic oncogene (Baron et al. 2004). 
Inhibition of this enzyme is selectively toxic to 
cancer cells (Lupu and Menendez, 2006). In addi-
tion, activated AKT inhibits fatty acid oxidation 
and contributes to fatty acid synthesis via suppres-
sion of carnitine palmitoyltransferase 1A (CPT1A) 
(Buzzai et al. 2005; Vankoningsloo et al. 2005; 
DeBerardinis et al. 2006). However, it is not clear, 
how the large amounts of cytosolic acetyl-CoA, 
which are required for the de novo synthesis 
of fatty acids, are generated. Hatzivassiliou 
et al. (2005) suggested the formation of cytosolic 
acetyl-CoA via citrate, which is exported from 
mitochondria and cleaved by ATP Citrate Lyase 
(ACLY), but this mechanism requires activity of 71
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the mitochondrial PDC as well as a truncated 
tricarboxylic acid cycle (TCA). As described 
above, numerous mechanisms, including PI3K and 
HIF-1 activity, rather repress than activate PDC. 
In addition, several researchers propose a substan-
tial involvement of the PPP in the utilization of 
glucose in cancer cells (Boros et al. 1997; Rais 
et al. 1999; Cascante et al. 2000; Boros et al. 2002; 
Coy et al. 2005, see Fig. 1). The apparent difference 
between acetyl-CoA availability and utilization 
may be resolved by the identiﬁ  cation and initial 
functional characterization of transketolase-like 1 
(TKTL1), a novel enzyme with a putative key 
function in the fermentation of glucose within the 
PPP (Coy et al. 1996; Coy et al. 2005).
TKTL1, the Pentose Phosphate 
Pathway, and Elevated Lipogenesis 
in Cancer
Although the current literature on tumour metabo-
lism primarily focuses on the interplay between 
major oncogenic pathways and glucose degrada-
tion via the Embden-Meyerhof-pathway, there is 
evidence for a substantial involvement of the PPP 
in glucose metabolism in cancer cells (Fig. 1). Via 
its oxidative branch, the PPP delivers NADPH for 
reductive biosynthesis as well as for maintenance 
of the intracellular redox state and the detoxiﬁ  ca-
tion of ROS. Ribose for the synthesis of nucleic 
acids is contributed by both the oxidative as well 
as the non-oxidative branch. The importance of the 
PPP in cancer is underlined by the efﬁ  ciency of in 
vivo therapeutic approaches addressing the inhibi-
tion of this pathway (Rais et al. 1999; Ramos-
Montoya et al. 2006). The anti-tumourigenic effect 
of the thiamine analogue and transketolase inhib-
itor oxythiamine (OT) was already documented 
two centuries ago (Trebukhina et al. 1987). Trans-
ketolase represents the rate-limiting enzyme for 
the non-oxidative branch of the PPP, which is the 
main source for the generation of ribose for nucle-
otide synthesis within cancer cells (Boros et al. 
1997; Comin-Anduix et al. 2001). Suppression of 
both the oxidative branch (via the G6PD-inhibitor 
dehydroepiandrosterone [DHEA]) as well as the 
non-oxidative branch of PPP (via OT) was found 
to exert additive effects leading to the inhibition 
of cancer cell proliferation (Boros et al. 1997). 
Ramos-Montoya et al. (2006) recently demonstrated 
the relevance of PPP oxidative/non-odidative 
balance for cancer cell survival. Combinatorial 
application of the inhibitors methotrexate, DHEA, 
and OT which address different enzyme activities 
necessary for the utilization of glucose for the 
synthesis of nucleic acids, resulted in an almost 
complete inhibition of cancer cell proliferation 
(Ramos-Montoya et al. 2006). Also, inhibition of 
transketolase enzyme reactions by small molecules 
has been demonstrated to suppress proliferation in 
cancer cell lines (Du et al. 2004).
Basic reactions of the non-oxidative branch of 
the PPP were initially delineated in the early 1950s 
by Horecker, Gibbs, and colleagues, who applied 
enzyme preparations from liver and pea tissues 
(Gibbs and Horecker, 1954; Horecker et al. 1954). 
Using acetone dry powder preparations of enzymes 
and radioactively labelled substrates, the scientists 
were able to determine reaction sequences and 
stoichometries in the absence of oxidative metab-
olism. However, although the experimental data 
could not be explained by the reaction scheme 
proposed, the latter was presented as a part of a 
new metabolic pathway (Horecker and Mehler, 
1955). Consecutively, this pathway was commonly 
accepted by text-book authors. Nevertheless, until 
now the stoichometries of the non-oxidative PPP 
remained a matter of debate (reviewed in Williams 
et al. 1987).
The identiﬁ  cation of   TKTL1, which partici-
pates in glucose metabolism in cancer cells, sheds 
a new light on this pathway, as TKTL1 represents 
an enzyme with transketolase activity and a poten-
tially elevated substrate spectrum with altered 
reaction characteristics (Coy et al. 2005). Subse-
quently, TKTL1 was found to be overexpressed in 
a wide variety of solid cancers and signiﬁ  cantly 
correlated with aggressiveness in different carci-
noma entities (Langbein et al. 2006; Staiger et al. 
2006; Krockenberger et al. 2007; Foldi et al. 2007). 
TKTL1 expression was further linked to the fer-
mentation of glucose by its elevated expression in 
normal tissues like testis and retina, which were 
already described by Warburg to perform aerobic 
glycolysis (Warburg et al. 1924; Coy et al. 2005). 
The signiﬁ  cance of TKTL1-activity for both pro-
liferation and glucose metabolism in cancer was 
recently demonstrated in functional studies using 
RNA interference (Zhang et al. 2007; Hu et al. 
2007). Inhibition of TKTL1 was found to mediate 
elevated apoptosis, cell cycle arrest in the G1-phase, 
as well as a substantial reduction of transketolase 
activity. The latter ﬁ  nding was particularly interest-
ing for a re-interpretation of the activity of the PPP 72
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within cancer cells. Although TKTL1 accounted 
for approx 50% of the total transketolase content 
(TKT, TKTL1, TKTL2) at the mRNA level prior 
to RNAi-mediated suppression, targeted knock-
down of TKTL1 resulted in a 50% inhibition of 
total transketolase activity. As transketolase usually 
exists as a dimer, and the subunits cooperatively 
regulate the enzymatic activity of the complex 
(Frank et al. 2004), the latter ﬁ  nding may reﬂ  ect a 
regulatory effect of TKTL1 on whole transketolase 
activity via heterodimerization of the enzyme with 
other transketolase homologues.
The classical transketolase reaction is described 
as the transfer of a 2 carbon unit from ketose sug-
ars to aldose sugars (Kochetov, 1982). The reaction 
mechanism includes the formation of an activated 
glycolic aldehyde, which is subsequently trans-
ferred to the aldehyde group of the aldose acceptor 
substrate. Besides the 2 substrate reaction described 
above, TKTL1 was found to efﬁ  ciently catalyze a 
one-substrate reaction, where the ketose sugar 
xylulose-5-phosphate (Xu5P) is cleaved in 
glycerinaldehyde-3-phosphate (GAP) and a 2 car-
bon product of yet unknown nature (Coy et al. 
2005). This particular reactivity of TKTL1 can be 
explained by the loss of one exon encoding for a 
stretch of 38 amino acids (compared to human 
TKT), which contains highly conserved residues 
invariant for all transketolase proteins analysed so 
far (Coy et al. 1996). One of these residues, which 
corresponds to His103 in yeast transketolase, has 
been demonstrated to contribute to substrate spe-
ciﬁ  city using the yeast enzyme (Wikner et al. 
1995). Targeted mutation of His103 to alanine has 
been found to accelerate the one-substrate reaction, 
while the two substrate reaction was decelerated 
(Selivanov et al. 2004). Therefore, it is conceivable 
that TKTL1 signiﬁ  cantly contributes to the elevated 
fermentation of glucose observed in tumours by 
the cleavage of Xu5P, a putatively irreversible 
activity which alters the concentration of this 
metabolite within the balanced equilibrium of 
sugars in the cytoplasm.
The balance of glucose utilization within the 
cell is highly regulated, and Xu5P was found to 
represent a messenger, the concentration of which 
is crucial for the coordinated regulation of the 
Embden-Meyerhof glycolytic pathway and the PPP 
(Nishimura et al. 1994; Doiron et al. 1996). In 
hepatocytes, Xu5P exerts its effect via the activa-
tion of Xu5P-activated protein phosphatase 2A 
(PP2A). This enzyme complex accelerates the 
Embden-Meyerhof glycolytic pathway by the 
dephophorylation of Fructose-6-phosphate, 
2-kinase:Fructose-2,6-bisphosphatase, which itself 
activates phosphofructokinase by elevating the 
Fructose-2,6 bisphosphate levels (Nishimura and 
Uyeda, 1995). Furthermore, Xu5P-activated PP2A 
was found to induce transactivation of enzymes 
required for glucose-induced lipogenesis, which is 
mediated by dephophorylation and nuclear 
translocation of carbohydrate response element-
binding protein (ChREBP) (Yamashita et al. 
2001; Kabashima et al. 2003; Veech, 2003). Taken 
together, the levels of Xu5P regulate the Xu5P – 
PP2A—ChREBP axis for glucose utilization 
within the liver cell. The TKTL1 gene harbours a 
putative ChREBP binding site within its upstream 
regulatory region, which suggests a potential 
involvement of this axis in the regulation of 
TKTL1-activity. Intriguingly, Vankoningsloo et al. 
(2005) detected elevated ChREBP transactivation 
activity, glucose-induced lipogenesis, activation 
of PI3K-signalling, and suppression of fatty acid 
beta oxidation in mouse 3T3L1 pre-adipocytes 
after treatment with antimycin A, an inhibitor of 
OXPHOS (Vankoningsloo et al. 2005). These 
results demonstrate, that Xu5P signalling is not 
exclusive to cells of hepatocytic origin, but may 
rather represent a more ubiquitous mechanism for 
the regulation of glucose metabolism. Furthermore, 
the inactivation of OXPHOS and the resulting 
metabolic features in pre-adipocytes closely resem-
ble the frequently described characteristics of 
aggressive cancer cells.
Given the inconsistencies in the exact stoi-
chometries of the reactions of the PPP, the unclear 
origin of the large amounts of cytosolic acetyl-CoA 
for lipid synthesis within cancer cells, and ﬁ  nally 
the novel role of TKTL1 in glucose fermentation 
within cancer cells, the mechanisms leading to 
aerobic glycolysis need re-evaluation. It remains 
to be determined whether the enzymatic activity 
of TKTL1 contributes to glucose-induced lipogen-
esis, loss of OXPHOS, and the formation of lactate 
in aggressive cancer cells. However, TKTL1-
expression correlates with this metabolism, and 
the cleavage of Xu5P could offer novel mechanis-
tic perspectives for both the regulation of glucose 
metabolism via the Xu5P/PP2A/ChREBP axis 
and the origin of abundant cytosolic acetyl-CoA 
for lipogenesis. As both the targeted knockdown 
of TKTL1 expression as well as the compound-
mediated inhibition of transketolase activity exerts 73
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strong inhibition of tumour growth, TKTL1 
represents an excellent candidate for a targeted 
treatment of aggressive carcinomas.
The Consequences of Aerobic 
Glycolysis: Therapy Resistance, 
Matrix-Degradation, Angiogenesis, 
and Suppression of the Immune 
System
It is well documented, that elevated fermentation 
of glucose, loss of OXPHOS, and the formation of 
lactate confer selective advantages to aggressive 
cancer cells (reviewed in Gatenby and Gillies, 
2004). Although there is substantial evidence, that 
the generation of ROS reﬂ  ects mitochondrial mal-
function, either hypoxia-induced or due to mutated 
components of the mitochondrial electron transport 
chain, it is not yet clear (and most probably 
context-dependent) whether elevated ROS are 
rather advantageous or detrimental to the cancer 
cell (reviewed in Fruehauf and Meyskens, 2007).
Loss of OXPHOS and fermentation of large 
amounts of glucose has been mechanistically 
linked to the activation of the AKT survival path-
way through the redox-mediated inactivation of 
PTEN (Pelicano et al. 2006b). Activation of AKT 
coincided with elevated resistance to several 
common anticancer drugs, irrespective of 
their intracellular targets, as well as with 
enhanced susceptibility to cell death induced by 
3-Bromopyruvate, an inhibitor of glycolysis 
(Xu et al. 2005). In 2001, Gottlob et al. identiﬁ  ed 
a mechanism of apoptosis suppression which is 
mediated by activated AKT and requires the pres-
ence of glucose, as well as the translocation of 
hexokinase (HK) to mitochondria (Gottlob et al. 
2001). Mitochondria-targeted HK prevents apop-
tosis by antagonizing the release of mitochondrial 
cytochrome C (Majewski et al. 2004). However, 
whether this mechanism contributes to the 
enhanced resistance to anticancer agents in 
OXPHOS-depleted cancer cells featuring acti-
vated AKT remains to be investigated. As 
discussed above in more detail, also HIF-1 con-
tributes to the phenotypic expression of different 
hallmarks of aggressive cancer and is associated 
with increased patient mortality in different cancer 
types (reviewed in Semenza, 2003).
At a systemic level, the elevated needs for 
glucose mediated by the Warburg effect may con-
tribute to apparent alterations in cancer patients, 
which ultimately lead to cancer cachexia. Different 
studies documented an elevated glucose production 
in cachectic cancer patients, as well as metabolic 
abnormalities resembling those of type II diabetes 
mellitus (Holroyde et al. 1975, 1984; reviewed in 
Tayek, 1992). It has been suggested, that lactate 
production of tumours may represent a source for 
elevated hepatic glucose production in tumour-
bearing humans (Tayek, 1992). Gluconeogenesis 
was found to substantially contribute to glucose 
production in a subgroup of cancer patients, and 
this metabolic activity was tightly correlated with 
elevated levels of serum cortisol (Tayek and Katz, 
1997). Notably, several studies revealed a resist-
ance of carcinoma cells to cytotoxic cancer therapy 
subsequent to the administration of glucocorticoids 
(GC) both in vitro and in vivo (Rieger et al. 1999; 
Herr et al. 2003). GC-mediated gluconeogenesis 
and subsequent mobilization of glucose may also 
further worsen the metabolic situation of the can-
cer patient. These data raise concerns about the 
frequently applied GC treatment for the suppres-
sion of cancer cachexia (Herr and Pﬁ  tzenmaier, 
2006).
The formation of lactate, one of the end products 
of aerobic glycolysis, contributes to the acidiﬁ  ca-
tion of the microenvironment of cancer cells. 
Elevated levels of intratumoural lactate were found 
to correlate with the likelihood of distant metas-
tases as well as with restricted patient survival 
(Walenta et al. 2000). Intracellular lactate is trans-
ported across the cytoplasmic membrane by 
members of a family of proton-coupled monocar-
boxylate transporters (MCT) (Enerson and Drewes, 
2003). Of these, MCT4 was found to be upregu-
lated in a HIF-1 and PI3K-dependent manner 
(Moeller et al. 2005; Ullah et al. 2006), and is 
predominantly expressed in cells or tissues which 
rely on glycolysis for the generation of ATP 
(Dimmer et al. 2000). Once transported to the 
extracellular space, lactate initiates multiple 
activities which predominantly favour the growth 
and metastasis of cancers. A lactate-mediated 
acidiﬁ  cation of the extracellular matrix (ECM) 
contributes to apoptosis in susceptible cells. How-
ever, this mechanism requires functional p53, a 
tumour suppressor which is frequently inactivated 
in advanced carcinomas (Williams et al. 1999). 
Therefore, aerobic glycolysis and the formation of 
lactate selects for the growth of (aggressive) cancer 
cells, which already harbour defects in tumour-
suppressive pathways. The remodelling of the 74
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ECM is a prerequisite for invasive growth, and 
lactate contributes to this process via the modula-
tion of ﬁ  broblasts and the activation of matrix 
metalloproteases (MMPs), which are required for 
the digestion of ECM-components. Lactate is able 
to stimulate the expression of the ECM-component 
hyaluronan (HA) and its cell surface receptor CD44 
in ﬁ  broblasts (Stern et al. 2002). A HA-enriched 
microenvironment contributes to cancer cell sur-
vival and metastasis by promoting cancer cell 
migration (Zhu and Bourguignon, 2000), by 
enhancing anchorage-independent growth of can-
cer cells (Kosaki et al. 1999), and by the suppres-
sion of tumour immunogenicity (McBride and 
Bard, 1979) and tumour cell apoptosis (Yu et al. 
1997). The acidic environment of aggressive can-
cer cells can promote the activation of MMPs 
(reviewed in Chaussain-Miller et al. 2006). The 
transcription of MMPs in cancer cells can be forced 
by CD147 (alias EMMPRIN), which is frequently 
expressed in human cancer (Riethdorf et al. 2006). 
CD147 maturation and targeting to the cytoplasmic 
membrane is regulated by MCT4, which provides 
a mechanistic link between lactate efﬂ  ux and ECM 
remodelling (Gallagher et al. 2007). Intriguingly, 
CD147-expression on ovarian carcinoma cell line 
derived microvesicles was also demonstrated to 
stimulate proangiogenic activities of endothelial 
cells in vitro, suggesting a role of CD147 in 
tumour-angiogenesis (Millimaggi et al. 2007). By 
coupling the glycolytic phenotype to ECM-degra-
dation and angiogenesis, the synergistic function 
of MCT4 and CD147 reﬂ  ects the intimate relation-
ship between the Warburg effect and the aggres-
siveness of tumours exhibiting this phenotype. In 
addition, lactate-mediated acidification of the 
tumour-microenvironment strongly suppresses 
proliferation and cytokine production of human 
cytotoxic T-lymphocytes (Fischer et al. 2007). This 
ﬁ  nding may explain the frequently observed inabil-
ity of the immune system to control aggressive 
cancer despite of a speciﬁ  c T-cell response against 
tumour-associated antigens.
The discussion about the role of ROS in cancer 
is rather controversial. It has been proposed that 
aerobic glycolysis and the generation of mitochon-
drial ROS are intimately linked (Wallace, 2005; 
Schumacker, 2006). Also, it is commonly accepted, 
that ROS can damage DNA and thereby contribute 
to genetic instability. This might be a mechanism 
for cancer initiation and progression, but the over-
expression of the ROS-detoxifying enzyme 
thioredoxin-reductase 1 (TR1) in a variety of 
malignant tumours rather suggests, that malignant 
cancers may need a delicate balance between ROS 
production and neutralization for oncogenic signal-
ling, survival and resistance to therapy (Yoo et al. 
2006). The neutralization of ROS by the intracel-
lular enzyme system requires NADPH, which is 
mainly contributed by the PPP. In this context, it 
is not surprising that bacteria were demonstrated 
to exhibit elevated radioresistance, when glucose 
was predominantly metabolized by the PPP (Zhang 
et al. 2000). Aggressive glioblastoma cells, which 
frequently exhibit a high degree of resistance to 
antitumour therapies, revealed an increased expres-
sion of antioxidant enzymes when selected for 
radioresistance (Lee et al. 2004). An elevated for-
mation of the superoxide radical via experimental 
inhibition of mitochondrial electron transport 
complex I was demonstrated to sensitize leukemia 
cells to anticancer agents whose action involves 
free radical generation (Pelicano et al. 2003). In 
summary, although promoting genetic instability 
and oncogenic signalling (by e.g. HIF-1, see 
above), ROS may be detrimental for the cancer 
cell under selection of antitumour therapy. There-
fore, avoiding ROS by the elevated activity of 
ROS-detoxifying enzymes, shutdown of OXPHOS, 
as well as the utilization of PPP for the fermenta-
tion of glucose may be a suitable strategy of cancer 
cells for the development of resistance to radio- and 
chemotherapy.
Cancer Treatment by the Suppression 
of the Warburg Effect
The Warburg effect is an almost universal hallmark 
of aggressive cancer, and since considerable evi-
dence suggests that this particular metabolism 
actively contributes to cancer progression and 
metastasis, it is reasonable to develop anticancer 
strategies which target this phenotype. Indeed, 
experimental data suggest that the reversion of 
single metabolic features of the glycolytic pheno-
type negatively inﬂ  uences the aggressive properties 
of cancer cells. Substrate limitation as the most 
simple approach has been demonstrated to initiate 
death of cancer cells in vitro (Elstrom et al. 2004) 
and suppression of tumour growth in both mice 
(Zhou et al. 2007) and humans (Nebeling et al. 
1995). As already discussed throughout this 
manuscript, an inhibition of key enzymes of 
affected metabolic pathways was also found to 75
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compromise growth of tumour cells (also reviewed 
in Pelicano et al. 2006a). Finally, there is increas-
ing evidence that dietary components such as 
certain polyunsaturated fatty acids (PUFA) and 
plant polyphenols interfere with the glycolytic 
phenotype of cancer cells, and that their adminis-
tration provides positive effects in the treatment of 
cancer.
Besides the inhibition of glycolysis and 
glucose-induced lipogenesis, experimental reac-
tivation of mitochondrial OXPHOS by both 
genetic as well as pharmacological approaches has 
also been demonstrated to efﬁ  ciently counteract 
the growth of cancer both in vitro and in vivo. 
Overexpression of frataxin, a protein which shows 
reduced expression in individuals suffering from 
the inherited Friedreich ataxia disease (Campuzano 
et al. 1997), has been shown to reduce the growth 
of cancer cells in vitro as well in a mouse xenograft 
model (Schulz et al. 2006). Frataxin contributes 
to the intramitochondrial synthesis of Fe/S 
clusters, which are obligate components of 
the respiratory chain (reviewed in Lill and 
Muhlenhoff, 2005). Upon overexpression, the 
tumour-suppressive function of frataxin was found 
to correlate with decreased phosphorylation of 
oncogenic extracellular signal-regulated kinase 
(ERK), increased phosphorylation and activation 
of the tumour suppressor p38 MAP kinase, and 
the reactivation of OXPHOS in different human 
colon cancer cell lines. In line with these results, 
targeted disruption of hepatic frataxin in mice was 
found to mediate the formation of elevated ROS, 
impaired phosphorylation of p38 MAP kinase, 
reduced activity of Fe/S cluster-containing pro-
teins, and impaired OXPHOS in hepatocytes 
(Thierbach et al. 2005). As a result of these 
alterations, mice developed multiple hepatic 
tumours and had a signiﬁ  cantly reduced life span. 
The importance of frataxin as an essential com-
ponent of mitochondrial homeostasis clearly 
underlines the relevance of mitochondrial integrity 
for cancer suppression.
The pharmacologic reactivation of the mito-
chondrial PDC by dichloroacetate (DCA) was 
recently found to mediate profound suppressive 
effects on tumour growth both in vitro and in vivo 
(Bonnet et al. 2007). DCA inhibited PDK, which 
induced glucose oxidation in cancer cells. This 
metabolic shift coincided with a reduction of the 
mitochondrial membrane potential, an increase in 
mitochondrial ROS, and an increase in expression 
of the mitochondrial K
+ channel protein Kv1.5, 
resulting in cancer cell apoptosis.
Although the studies on frataxin and DCA 
clearly show, that reactivation of OXPHOS is a 
promising strategy for anticancer treatment, other 
studies revealed differences in the reactivation 
capacity of tumour cell mitochondria among dif-
ferent cell lines. Rossignol and colleagues demon-
strated a variability of substrate utilization and 
oxidative capacity in HeLa cells, where energy 
generation via forced OXPHOS correlated with an 
alteration of mitochondrial structure. Oxidative 
metabolism reduced the proliferation rate of HeLa 
cells, but did not result in cell death (Rossignol 
et al. 2004). In another study, a metabolic analysis 
of the non small cell lung cancer cell lines H460 
and A549 revealed, that both cell lines exhibited 
considerable dependency on glycolysis. The extent 
of this dependency was different, but intimately 
linked to the impairment of OXPHOS, respectively 
(Wu et al. 2007). In HT29 colon cancer cells, the 
application of (oxidizable) butyrate as an energy 
substrate was found to initiate a differentiation 
process, whereas butyrate-resistant MIA pancreatic 
adenocarcinoma did not differentiate (Boren et al. 
2003). These data may not be representative or 
comprehensive, but they clearly demonstrate, that 
there is substantial variability in the response of 
different cancer cells on the modulation of 
OXPHOS. The responses include reduced prolif-
eration, cell cycle arrest, cell death, and differen-
tiation. To which extent these responses contribute 
to a therapeutic success in vivo remains to be 
investigated. The intracellular balance of ROS 
elimination and formation, the latter of which may 
reﬂ  ect the degree of damage in the mitochondrial 
electron transport chain, may play a major role in 
the cellular response to forced OXPHOS. In con-
clusion, substrate limitation or speciﬁ  c inhibition 
of glucose fermentation may represent a more 
comprehensive therapeutic option, because these 
approaches do not aim at the reactivation of a 
tumour-suppressive process, but instead target the 
essential (“oncogenic”) process of energy genera-
tion in cancer cells.
Certain dietary components, which have been 
identiﬁ  ed to enhance the positive effects of chem-
otherapy, may also interfere with the Warburg 
effect. The application of omega-3 (n-3) fatty acids 
was repeatedly demonstrated to enhance the 
tumour cytotoxic effects of chemotherapy, to 
improve the quality of life during therapy, while 76
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reducing cancer cachexia (reviewed in Hardman, 
2004). PUFA, including n-6 and n-3 fatty acids, 
were recently found to suppress glycolytic and 
lipogenic gene expression in a ChREBP-dependent 
manner (Dentin et al. 2005). Whether this mecha-
nism contributes to the observed beneﬁ  cial effects 
of n-3 fatty acids by modulation of the Warburg 
effect in cancer cells remains to be investigated.
Several plant polyphenols, which are also fre-
quently categorized as antioxidants, were found to 
exert beneﬁ  cial effects in the treatment of cancer, 
predominantly by a sensitization of tumour cells 
to chemo- and radiotherapy (reviewed in Garg et al. 
2005). The application of resveratrol, a constituent 
of red wine, induced cell cycle arrest in lymphoma 
cells, which coincided with the inhibition of 
PI3K-mediated glucose metabolism (Faber et al. 
2006). Resveratrol also stimulates the PGC-
1α-mediated expression of genes required for 
OXPHOS by enhancing the afﬁ  nity of NAD+ to 
the histone deacetylase Sirt1 (Lagouge et al. 2006). 
In this context, the application of resveratrol mim-
ics the effects of physical exercise or fasting, 
resulting in an improvement of mitochondrial func-
tion and elevated OXPHOS. This mechanism may 
contribute to the anti-tumourigenic effects of res-
veratrol, and there is evidence, that other plant 
polyphenols, e.g. curcumin, also interfere with 
mitochondrial activity and the generation of ROS 
(Garg et al. 2005; Su et al. 2006). Recently, a com-
bined application of plant polyphenols and PUFA 
within a standardized study for advanced cancer 
patients with cancer anorexia/cachexia and oxida-
tive stress revealed safety and efﬁ  ciency with 
regard to the improvement of clinical, nutritional, 
and laboratory features as well as the quality of 
life (Mantovani et al. 2006)
In summary, both the inhibition of glucose fer-
mentation (via specific inhibition of enzymes 
and/or dietary intervention) as well as the reactiva-
tion of OXPHOS exert a tumour-suppressive effect 
on cancer cells, which should be further investi-
gated for the development of novel therapeutic 
strategies. Within this cellular response, the role 
of ROS is probably important, but a causative 
involvement of ROS remains enigmatic and 
requires further analysis. In mice, the dietary sub-
strate limitation by the application of a ketogenic 
diet in a low-caloric dosage reduced tumour growth 
(Zhou et al. 2007), which suggests an antitumour 
effect that is mainly based on caloric restriction. 
However, to prevent cancer-cachexia, we propose 
the application of a carbohydrate-restricted 
nutrition, which includes signiﬁ  cant amounts of 
(n-3) fatty acids as well as selected plant polyphe-
nols. Considering the observations discussed 
above, this strategy could represent a novel and 
promising approach for a diet-based intervention 
against aggressive cancer.
Conclusions
It has been experimentally demonstrated, that the 
inhibition of glucose fermentation, substrate limi-
tation, inhibition of lactate generation, inhibition 
of glucose-induced lipogenesis, as well as the 
reactivation of OXPHOS represent promising 
strategies for cancer therapy. Therefore it seems, 
that all of the features which characterize the 
metabolism of aggressive cancer, are essential for 
its phenotype. Clinically, the altered glucose 
metabolism in cancer patients is often reﬂ  ected by 
apparent systemic metabolic abnormalities, which 
resemble those seen in type II diabetes mellitus 
and frequently result in cancer cachexia (Tayek, 
1992). Since both metastatic growth of cancer cells 
as well as cachexia represent major causes of can-
cer-related death, the investigation of pharmaco-
logical and diet-based approaches against glucose 
fermentation of tumours is of utmost importance.
TKTL1, one of three human transketolase 
homologues, most likely plays a key role in aero-
bic glycolysis. Besides a positive correlation of 
TKTL1-expression, aerobic glycolysis, and the 
aggressiveness of different cancer types, targeted 
knockdown of TKTL1 in vitro already demon-
strated its functional relevance for both growth and 
metabolism of cancer cells (Coy et al. 2005; Lang-
bein et al. 2006; Krockenberger et al. 2007; Zhang 
et al. 2007; Hu et al. 2007).
Given the novel role of TKTL1 in the metabo-
lism of aggressive cancer cells, as discussed within 
this article, the pathways of glucose fermentation 
require a thorough re-evaluation. The glycolytic 
phenotype enables cell survival by a rapid utiliza-
tion of large amounts of glucose in the absence of 
OXPHOS. This metabolism may support a prolif-
erative phenotype in the absence of ROS in both 
cancer and normal cells (Brand and Hermﬁ  sse, 
1997). Notably, recent studies in lymphocytes sug-
gest a role of PI3K signalling in the glycolytic 
control of cell growth, where entry into the S-phase 
of the cell cycle is preceded by a shift to lactate 
production via the PPP (Doughty et al. 2006). 77
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Utilization of the PPP may reﬂ  ect the cellular 
demand for ROS-free glucose-derived energy dur-
ing replication and subsequent cell division, since 
genomic DNA is temporarily unprotected in these 
phases. It has been demonstrated, that elevated 
ROS during replication may provoke telomere loss 
leading to the inhibition of proliferation and 
cellular senescence (von Zqlinicki et al. 1995, 
Matthews et al. 2006). During cell division, com-
partmentalization is partially abolished. In this 
situation, cellular respiration would release ROS 
into the same compartment where genomic DNA 
is located, which could cause severe DNA muta-
tions. Otherwise, a mitochondria-independent 
energy production via TKTL1-mediated fermenta-
tion of glucose within the PPP would minimize 
ROS release.
Consistent with the proposed role of TKTL1 in 
energy generation during the cell cycle, Warburg 
already described that aerobic glycolysis is not 
restricted to cancer, but also occurs in healthy tis-
sues like e.g. testis and retina (Warburg et al. 1924). 
Besides in these two tissues, the TKTL1 protein is 
also strongly expressed in endothelial and neuronal 
cells (Coy et al. 2005). In testicular tissue, male 
germ cells exhibit a high proliferative rate, and 
DNA of these cells must be protected against ROS 
induced mutations during replication, which may 
be supported by a fermentative glucose metabolism 
mediated by TKTL1. A similar strategy, favouring 
rapid cell growth and avoiding DNA mutations, 
may be applied by cancer cells which exploit the 
fermentative glucose metabolism for energy pro-
duction. The protective effect of the fermentative 
energy production is most probably based on an 
ATP production without the formation of mito-
chondrial ROS, as well as on the efﬁ  cient produc-
tion of NADPH (and concomitantly reduced 
glutathione) via the oxidative part of the PPP. As 
a consequence, cancer cells with metabolically 
active mitochondria (OXPHOS) are more sensitive 
against standard cancer therapies, whereas cancer 
cells with a fermentative energy production are 
resistant against most standard chemotherapies 
(Pelicano et al. 2003; Xu et al. 2005). In retina, 
endothelia, and neuronal cells, a major function of 
TKTL1 could be the rapid elimination of large 
amounts of glucose. Thereby, TKTL1 may prevent 
the formation of toxic glucose adducts (advanced 
glycation end products,  AGE), which are frequently 
seen in diabetic lesions and neurodegenerative 
diseases. This suggestion lends support from the 
ﬁ  nding, that the administration of benfotiamine 
(an analogon of the cofactor thiamine and transke-
tolase activator) blocks hyperglycaemic damage 
and prevents experimental diabetic retinopathy in 
mice (Hammes et al. 2003). We propose, that 
TKTL1 mediates aerobic glycolysis, which pre-
vents hyperglycaemic damage as well as the forma-
tion of ROS, and which may be a prerequisite for 
rapid cell growth as observed in both male germ 
cells and cancer. Therefore, the enzymatic function 
of TKTL1 seems Janus-faced, exerting both protec-
tive as well as destructive effects for the organism. 
In the case of cancer, the switch from OXPHOS 
to a predominant/obligatory fermentative metabo-
lism seems to occur with differential efﬁ  ciency 
within different tissues, and this might be reﬂ  ected 
by the respective frequencies of aggressive 
tumours. Whereas epithelial tissues are frequently 
affected from metastatic cancer, mesenchymal tis-
sues, e.g. the heart muscle, very rarely develop 
aggressive neoplasia. This may be caused by the 
preference of these tissues for an oxidative metab-
olism. Even in the presence of glucose, the heart 
muscle preferentially utilizes fatty acids, ketone 
bodies, or lactate for an oxidative generation of 
ATP. Interestingly, the heart muscle strongly 
expresses a short splice variant of TKTL1, which 
putatively encodes for a N-terminally truncated 
isoform of the protein (Coy et al. 1996).
The modern western lifestyle is characterized 
by a dramatic decrease in physical activities as well 
as by the ingestion of food displaying a high gly-
caemic index, which results in an intermittent fast 
and strong increase in blood glucose level, massive 
secretion of insulin, and extensive glycogen stor-
age. In parallel, the incidence of pathological 
metabolic conditions such as obesity, type 2 dia-
betes, and the metabolic syndrome is rising con-
tinuously. These metabolic disturbances are 
associated with increased incidence and/or mortal-
ity for a number of cancers (Giovannucci and 
Michaud, 2007). We propose, that the protective 
capacity of the TKTL1-pathway is not sufﬁ  cient 
to compete with a chronic glycaemic overload, a 
condition which favours the development of several 
civilization-related diseases like the Alzheimer 
disease, type 2 diabetes, and the metabolic syn-
drome. On the other hand, the elevated availability 
of glucose predisposes cancerous cells to switch 
from OXPHOS to a fermentative metabolism in 
both the absence and presence of oxygen, which 
favours an aggressive phenotype. The latter 78
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suggestion is further supported by studies which 
link physical activities (and thereby the reduction 
of glycogen reserves) to elevated cancer survival 
in humans (Demark-Wahnefried, 2006) and atten-
uated tumour growth in animals (Michna et al. 
2006; Colbert et al. 2006). In line with this idea, 
human populations which traditionally ingest a 
low-carbohydrate diet which is combined with 
high amounts of protein and PUFA, reveal a 
comparatively low incidence of aggressive cancer 
(Stefansson, 1960). Also, domestic animals 
(e.g. cats and dogs) which usually consume western 
diets with a comparatively high glycaemic index, 
frequently suffer from aggressive cancer, whereas 
carnivore animals and herbivore animals do have 
a low rate of metastasizing cancer and rarely die 
from this disease. Both carnivores and herbivores 
predominantly live from proteins and fat/oil. 
Although herbivores ingest large amounts of com-
plex carbohydrates (cellulose and other ﬁ  bres), 
these are fermented to fatty acids by bacteria within 
the gastrointestinal tract and therefore exhibit an 
extremely low glycaemic index. Both the herbivore 
as well as the carnivore type of diet are well estab-
lished during evolution, and due to the low glycae-
mic index, both do not further result in the secretion 
of excessive amounts of insulin. Since glucose 
represents the substrate necessary for a switch from 
an OXPHOS-mediated ATP production to a fer-
mentative ATP production, limited release or even 
absence of glucose during digestion may explain 
the low rates of cancer-caused mortality in herbiv-
ore and carnivore animals.
Otto Warburg reasoned, that a fermentative 
metabolism of glucose would be a more ancient 
way for the generation of energy, which is less 
susceptible to disturbances mediated by gene muta-
tions, as e.g. in the case of cancer. In contrast, the 
mitochondria-based energy production is highly 
efﬁ  cient, but very sensitive to inactivating events. 
DNA of mitochondria, organelles originating from 
bacteria which have been integrated during evolu-
tion, is more sensitive to mutations than nuclear 
DNA due to reduced repair mechanisms and a 
higher density of coding DNA. Mitochondrial 
DNA mutations, unspeciﬁ  c antibiotics which also 
inhibit mitochondria, as well as pesticids and heavy 
metals, which in part inactivate mitochondria, can 
favour a shift from a mitochondria-based energy 
production to energy production by glucose fer-
mentation, which is less susceptible to mutational 
damage. For affected cells, this shift may be 
further facilitated by an evolutionary novel 
microenvironment within the organism itself, 
which is characterized by a permanent availability 
of high amounts of glucose due to a nutrition with 
a high glycaemic index, the absence of periods of 
starvation, as well as reduced physical activity.
It remains to be determined, whether TKTL1 
plays a key role in the fermentative metabolism 
observed in the tissues, where the enzyme is 
strongly expressed. However, we propose that the 
high rate of carbohydrate ingestion may contribute 
to various metabolic diseases, including the devel-
opment of aggressive cancer. We further suggest 
that both dietary intervention as well as targeted 
modulation of TKTL1 glucose metabolism may be 
promising approaches for anticancer therapy as 
well as the treatment of other civilization-related 
diseases.
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